Kaleido Biosciences, Inc. (NASDAQ: KLDO) is a clinical‐stage biopharmaceutical company dedicated to developing novel small‐molecule therapeutics that harness the human microbiome to promote health. Using its proprietary Microbiome Metabolic Therapy (MMT) platform, Kaleido designs chemically defined glycans that selectively modulate microbial metabolic pathways. The company’s pipeline spans multiple candidates in clinical and preclinical stages targeting gastrointestinal, immunological and metabolic disorders.
Founded in 2015 and headquartered in Massachusetts, Kaleido applies its chemistry‐driven approach to identify and manufacture glycan‐based compounds capable of reshaping microbial communities without introducing living organisms. This strategy aims to deliver off‐the‐shelf therapies with established safety profiles, streamlined manufacturing and scalable distribution. Kaleido completed its initial public offering in July 2021, listing its shares on the NASDAQ under the symbol KLDO.
Kaleido’s lead candidate, KB195, is being evaluated for immunological and inflammatory conditions, while KB109 has been studied for its potential to alleviate gastrointestinal symptoms associated with viral infections. The company has entered multiple collaborations and partnerships to advance its pipeline, leveraging external expertise and infrastructure to accelerate development and broaden patient access.
Under the leadership of Chief Executive Officer Joern Aldag and a management team with deep experience in microbiology, chemistry and clinical development, Kaleido continues to expand its understanding of host‐microbiome interactions. While its programs currently focus on patients in the United States, the company plans to pursue regulatory approvals and commercial partnerships to extend its reach into global markets as its clinical programs mature.
AI Generated. May Contain Errors.
